Maier U, Kuber W, Loebenstein T
Fortschr Med. 1983 Jan 27;101(4):142-6.
The use of a new aminoglycosid antibiotic (dibekacin = Orbicin) in the treatment of severe urinary tract infections in a urological clinic is presented. After having given their written informed consent, 50 patients were treated with a dosage of 150-225 mg dibekacin, administered in three single daily doses. From a total of 41 mono-infections, asepsis could be attained in 70,7%, in 17,1% no effect could be observed and in 12,2% it came to a change of bacteria. From a total of 9 mixed infections, asepsis was observed only twice after the end of therapy. 87,5% of the patients reported about a far-reaching improvement or complete disappearance of clinical symptoms. In 2 cases allergic exanthema was observed. The local toleration was good. Disturbances of the otovestibular function were not registered.
本文介绍了一种新型氨基糖苷类抗生素（地贝卡星=奥贝星）在一家泌尿外科诊所治疗严重尿路感染中的应用。在获得患者书面知情同意后，50例患者接受了150 - 225毫克地贝卡星的剂量治疗，每日分三次单次给药。在总共41例单一感染中，70.7%实现了无菌，17.1%未观察到效果，12.2%出现了细菌变化。在总共9例混合感染中，治疗结束后仅观察到两次无菌情况。87.5%的患者报告临床症状有显著改善或完全消失。观察到2例过敏性皮疹。局部耐受性良好。未记录到耳前庭功能障碍。
